KS

Kevin Slawin

Chairman and CEO of PrintBio

Miami Beach, Florida

Overview 

Kevin Slawin is the Founder and CEO of Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc. in Houston, TX, pioneering the development of groundbreaking therapeutics to halt or reverse aging through advanced technologies. With a background in lifesciences and a successful track record in the biotechnology industry, he has also served as Chairman and CEO of PrintBio, Inc., demonstrating expertise in clinical strategy and pharmaceuticals. Kevin Slawin's career highlights include founding and leading multiple successful companies, such as Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., where he is at the forefront of innovative approaches to aging therapeutics. Additionally, his investment in companies like FIZE Medical and AsclepiX Therapeutics showcases his commitment to advancing healthcare through strategic investments.

Work Experience 

  • Chairman and CEO

    2023 - Current

    “Powered by Advanced and Clinically Tested Bioprinting Technologies” Our lead product is 3DMatrix™, a 3D-printed monofilament bioresorbable surgical mesh has received FDA 510(k) clearance.

  • Founder, CEO and Chairman

    2021

    Applying high throughput DNA encoded library (DEL) drug screening technologies in novel ways to deliver therapeutics that address the most difficult problems in clinical medicine

DELIVER Therapeutics provides modern research tools and approaches are rapidly implicating new types of disease.

  • Founder CEO and Chairman

    2019

    Using advanced, proprietary technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.

  • Founder and Managing Partner

    2018

    Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

Rapha Capital Management is an investment company that invests in early stage biotechnology companies.

  • Chairman of the Board

    2022

    Conquering the Last Frontier in Patient Monitoring. FIZE® Medical offers the first platform technology to remotely monitor and manage patients with an indwelling Foley catheter, providing unprecedented safety to both patients and their caregivers.

  • Board Member

    2020 - 2022

  • Founder and Chairman

    2021

    Physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami

Miami Medicos is a member organization supporting the business needs of Biopharma, medical devices and services companies.

  • Chairman of the Board

    2021

    Building a Best-in-class Urologic Oncology Company. Developing technologies to better visualize and treat urologic cancers through minimally invasive procedures in the physicians’ office

Imagin Medical is a surgical imaging company.

Raised $11,000,000.00 from Rapha Capital Management and Rapha Capital Management.

  • Founding Board Member

    2021

    Enabling promising early-stage life science companies to develop the next generation of innovative therapies to improve the lives of patients. We want to do this by offering them Contract Research Organization (CRO) Services, newly renovated wet-lab space, process and analytical development support, short-term financing, and third-party due diligence validation, among other services.

K2bio is a contract research organization that assists early-stage life science companies in advancing innovative therapies.

Raised $615,522.00.

  • Board Member

    2020

Demeetra AgBio is the issuance of licenses for agriculture, industrial biotechnology, and pharmaceutical bioprocessing.

  • Co-Founder, Managing Member and CMO

    2020

Articles About Kevin

Relevant Websites